Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. - Barron's
1. The biotech sector is in a frustrating year of stalled rallies so far. 2. XBI ETF shows resistance in the $87 area, impacting investor sentiment. 3. Amgen has solid growth potential and a dividend yield above 3%. 4. Technical analysis indicates a potential breakout above $311.38 for Amgen. 5. Other biotechs are outperforming, with notable gains contrasting Amgen's performance.